XORTX Is Making Gout Tablets. That's the Easy Part.

XORTX Therapeutics (Nasdaq: XRTX), a micro-cap Canadian clinical biopharma, announced Thursday that it has started contract manufacturing of XORLO, its gout drug — producing both clinical-grade oxypurinol and commercial-scale tablets. Management described the move as "a foundational step toward bringing XORLO to patients". The stock's own reply on the news: down roughly 2% on the day.

To see why the market shrugged, you first need to know what "starting manufacturing" actually buys. XORLO is a proprietary formulation of oxypurinol, the active metabolite of the cheap generic gout drug allopurinol, aimed at the small slice of patients — roughly 3–5% — who can't tolerate allopurinol. That sounds niche, and it is, but the economics behind it are real: febuxostat, the last branded entrant in the class, once topped $450 million in annual sales before a cardiovascular boxed warning dented it, and XORTX itself sizes the allopurinol-intolerant opportunity at roughly $700 million a year. The company plans to use the FDA's 505(b)(2) pathway, which lets it lean on existing data for the underlying molecule rather than re-prove it from scratch.

But here is the distinction that matters: manufacturing is the controllable, preparatory part of the story. The new drug material feeds the XRX-OXY-102 clinical study and generates the validation-and-stability data, plus commercial representative supply, that a New Drug Application needs. That is real box-ticking toward a filing. It does not, by itself, test the drug, shorten the timeline, or win approval.

The part that actually gates value at XORTX is the money. This is a pre-revenue company. It booked no revenue in 2025 and ended the year with about $864,000 in cash; by March 31, 2026, that had fallen to roughly $250,000, and the first quarter produced no new equity financing at all. Management's own 2026 budget for the gout program alone is $9 million to $18 million, with another $5 million to $10 million for the chemistry and manufacturing (CMC) work — inside a total 2026 activities estimate of $22 million to $64 million. In March, the company ran a 1-for-5 reverse split, cutting shares from about 7.0 million to 1.4 million, explicitly to keep the stock above Nasdaq's $1 minimum listing price.

So the milestone deserves a precise reading. XORTX is manufacturing the drug before it can pay to run the trial that tests it. As of the company's June update, the NDA was still a goal roughly 18 months out, contingent on an XRX-OXY-102 bridging study that compares XORLO against allopurinol in gout patients — a study still being set up, on top of an IND that was still in development. The manufacturing step is the cheapest, most controllable item on a long and expensive list.

For a retail investor deciding whether this changes anything, the useful frame is simple: in a pre-revenue biotech, a "commenced manufacturing" press release is a statement about logistics, not a change in the odds of approval. What moves XORTX's story — data from the XRX-OXY-102 study and the capital required to run it and reach a filing — is still ahead and still largely unfunded. Functional tablets in a warehouse are the easy part of a hard, dilutive road; the hard part, who pays for the rest of it, hasn't been answered yet.